Skip to main content

Advertisement

Fig. 4 | Journal for ImmunoTherapy of Cancer

Fig. 4

From: Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study

Fig. 4

Impact of combined variables of TMB on overall survival since the beginning of combined immunotherapy. TMB > 23.1 Mut/Mb (TMB-H) TMB ≤ 23.1 Mut/Mb (TMB-L). Log rank test for Trend. *significant. a Tumor mutation burden (TMB) and ctDNA measured by tumor-specific variant copies/ml of plasma detectable vs. undetectable at first follow-up p = 0.005*. b Tumor mutation burden (TMB) and ctDNA measured by tumor-specific variant copies/ml of plasma increasing vs. not increasing, p = 0.032*. c Tumor mutation burden (TMB) and cell-free DNA decrease > 50% vs. stable vs. increase > 50% at first follow-up, p = 0.016*. d Tumor mutation burden (TMB) and presence of liver metastases, p = 0.018*. e Tumor mutation burden (TMB) and sex, p = 0.010*

Back to article page